Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
4
×
boston
boston blog main
boston top stories
life sciences
4
×
national blog main
clinical trials
national top stories
dyne therapeutics
myotonic dystrophy type 1
rare disease drugs
san diego blog main
san francisco blog main
ally bridge group
astellas pharma
atlas venture
audentes therapeutics
avapritinib
avidity biosciences
big data analytics
biotech ipos
blackrock
bluebird bio
blueprint medicines
cancer
cancer drugs
capmatinib
casdin capital
diabetic nephropathy
duchenne muscular dystrophy
eli lilly
europe blog main
europe top stories
eventide asset management
facioscapulohumeral muscular dystrophy
fda
focal segmental glomerulosclerosis
gastrointestinal stromal tumors
gene therapy
genentech
What
drug
4
×
genetic
4
×
medicines
ipo
company
diseases
dyne
million
muscle
raised
rare
therapeutics
address
ago
analysis
approval
approves
bio
biotech
biotechs
blueprint
bring
brings
cancer
carries
certain
considering
data
designed
develop
developing
disorders
dyne’s
early
employing
expected
experimental
eyes
fda
goldfinch
Language
unset
Current search:
drug
×
biotech
×
" life sciences "
×
genetic
×
@xconomy.com
3 years ago
Dyne’s Upsized IPO Brings In $233M for Muscle Disorders Drug R&D
@xconomy.com
3 years ago
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
@xconomy.com
3 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
3 years ago
Goldfinch Raises $100M for Kidney Drug Studies Now, Perhaps an IPO Later